Empowered Funds LLC Sells 14,021 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Empowered Funds LLC lowered its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 72.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,410 shares of the biopharmaceutical company’s stock after selling 14,021 shares during the quarter. Empowered Funds LLC’s holdings in Alnylam Pharmaceuticals were worth $1,790,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. Geode Capital Management LLC raised its position in Alnylam Pharmaceuticals by 6.1% in the 4th quarter. Geode Capital Management LLC now owns 2,650,722 shares of the biopharmaceutical company’s stock worth $1,056,884,000 after purchasing an additional 151,480 shares during the period. Norges Bank purchased a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $895,816,000. Orbis Allan Gray Ltd boosted its position in shares of Alnylam Pharmaceuticals by 29.8% during the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock valued at $691,771,000 after buying an additional 486,489 shares during the period. Legal & General Group Plc grew its stake in shares of Alnylam Pharmaceuticals by 8.3% during the fourth quarter. Legal & General Group Plc now owns 961,496 shares of the biopharmaceutical company’s stock valued at $382,339,000 after buying an additional 73,716 shares during the last quarter. Finally, AQR Capital Management LLC grew its stake in shares of Alnylam Pharmaceuticals by 23.6% during the fourth quarter. AQR Capital Management LLC now owns 919,959 shares of the biopharmaceutical company’s stock valued at $365,822,000 after buying an additional 175,951 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ALNY. Raymond James Financial raised Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 price target for the company in a research note on Monday. Royal Bank Of Canada cut their price objective on Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating on the stock in a research report on Friday, July 31st. JPMorgan Chase & Co. reduced their target price on Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. Wells Fargo & Company lowered their target price on shares of Alnylam Pharmaceuticals from $377.00 to $316.00 and set an “equal weight” rating for the company in a research note on Friday, July 31st. Finally, Citigroup lowered their target price on shares of Alnylam Pharmaceuticals from $380.00 to $340.00 and set a “buy” rating for the company in a research note on Monday. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $396.72.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the sale, the director owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. This represents a 70.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 5.5%

Shares of Alnylam Pharmaceuticals stock opened at $216.12 on Friday. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 3.06. Alnylam Pharmaceuticals, Inc. has a 1 year low of $197.81 and a 1 year high of $495.55. The firm’s 50-day moving average is $281.78 and its two-hundred day moving average is $306.88. The stock has a market cap of $28.92 billion, a price-to-earnings ratio of 40.17 and a beta of 0.30.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.